Plus   Neg

Stock Alert: Genprex (GNPX)

Genprex, Inc. (GNPX) is currently trading at $1.60, an increase of 29 percent from the previous closing price of $1.24, following an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes.

Under the agreement, the Company has licensed the patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh. Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S.

On February 4, 2020, the Company regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT